{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:58:27Z","timestamp":1791460707614,"version":"4.3.4"},"reference-count":44,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Acute myeloid leukemia (AML) predominantly affects older adults; however, patients 75 years of age and older are often not candidates for curative-intent treatments. Data on their treatment patterns, survival outcomes, and healthcare utilization are limited, and we evaluated these outcomes among patients 75 years of age and older with AML. Methods: We retrospectively analyzed 97 patients aged 75 years and older managed at our academic safety-net hospital between 2016 and 2025. Results: Median overall survival (mOS) was 95 days for all patients. Receipt of any AML-directed therapy was associated with longer mOS compared with no leukemia-directed treatment (144 days, 95% CI: 98\u2013184 vs. 17 days, 95% CI: 7\u201350; p &lt; 0.001). Among patients with 2024 ELN adverse-risk\/TP53-mutated disease, mOS was 88 days (95% CI: 34-NE) with AML-directed therapy and 44 days (CI: 36-NE) without treatment (p = 0.2). Forty-four percent of patients were enrolled in a hospice at their time of death, and an additional 40% were managed with comfort measures as inpatients. Median duration of hospice or comfort care was 2 days (IQR: 1\u20135), with no difference based on whether patients received any AML-directed treatment. Fifty-one percent of patients died in the hospital. Conclusions: Our findings highlight real-world challenges for older adults with AML, including the need for more effective treatments for patients with TP53-mutated AML. AML-directed treatment was associated with longer survival without a decrease in the time spent in hospice care, and the risk of in-hospital mortality remains elevated for this population.<\/jats:p>","DOI":"10.3390\/cancers18193230","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:26:53Z","timestamp":1791458813000},"page":"3230","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contemporary Clinical Outcomes and Healthcare Utilization in Older Adults with Acute Myeloid Leukemia: Insights from a Single-Center Retrospective Cohort"],"prefix":"10.3390","volume":"18","author":[{"given":"Tina Y.","family":"Zhang","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Y.","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8208-1902","authenticated-orcid":false,"given":"Shyam A.","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poorva","family":"Bindal","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6602-5505","authenticated-orcid":false,"given":"Jan","family":"Cerny","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gillis-Smith","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthalagu","family":"Ramanathan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5452-6096","authenticated-orcid":false,"given":"Sakiko","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Pearson","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, MA 01655, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"108086","DOI":"10.1016\/j.leukres.2025.108086","article-title":"Treatment patterns and survival outcomes for very elderly patients with acute myeloid leukemia: A National Cancer Database study","volume":"157","author":"Zhang","year":"2025","journal-title":"Leuk. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3324\/haematol.2018.191536","article-title":"Genetics of acute myeloid leukemia in the elderly: Mutation spectrum and clinical impact in intensively treated patients aged 75 years or older","volume":"103","author":"Prassek","year":"2018","journal-title":"Haematologica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.beha.2018.09.010","article-title":"Patterns of mutations in TP53 mutated AML","volume":"31","author":"Welch","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53 -mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.2024027408","article-title":"Magrolimab plus azacitidine vs physician\u2019s choice for untreated TP53 -mutated acute myeloid leukemia: The ENHANCE-2 study","volume":"146","author":"Zeidner","year":"2025","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S2352-3026(22)00265-4","article-title":"Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: Pitfalls and recommendations","volume":"10","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-024-01000-2","article-title":"Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","volume":"14","author":"Badar","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1002\/cncr.33675","article-title":"Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy","volume":"127","author":"Venugopal","year":"2021","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3324\/haematol.2024.286465","article-title":"Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms","volume":"110","author":"Senapati","year":"2025","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1080\/10428194.2020.1759051","article-title":"Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: A single center experience","volume":"61","author":"Bewersdorf","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1002\/ajh.70422","article-title":"Limited Survival Benefit and High Healthcare Utilization with AML-Directed Therapy in Older Patients with TP53-Mutated Acute Myeloid Leukemia","volume":"9","author":"Zhang","year":"2026","journal-title":"Am. J. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/10428194.2016.1180688","article-title":"Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): The Lyon-university hospital experience","volume":"58","author":"Heiblig","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/leu.2015.188","article-title":"Treatment, trial participation and survival in adult acute myeloid leukemia: A population-based study in the Netherlands, 1989\u20132012","volume":"30","author":"Dinmohamed","year":"2016","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e70204","DOI":"10.1002\/cncr.70204","article-title":"Disparities in clinical trial participation among older adult Medicare beneficiaries with hematologic malignancies from 2006 to 2019: A SEER-Medicare analysis","volume":"131","author":"Gong","year":"2025","journal-title":"Cancer"},{"key":"ref_20","first-page":"e257076","article-title":"Unveiling Factors Associated With Older Adult Accrual to Cancer Clinical Trials: Lessons From the ECOG-ACRIN Experience","volume":"23","author":"Pearson","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/bloodadvances.2020001779","article-title":"Clinical outcomes of older patients with AML receiving hypomethylating agents: A large population-based study in the United States","volume":"4","author":"Zeidan","year":"2020","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2512120","DOI":"10.1080\/07853890.2025.2512120","article-title":"Significant prognostic improvement in elderly patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax: Outcomes from a retrospective real-world analysis","volume":"57","author":"Chen","year":"2025","journal-title":"Ann. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.21873\/anticanres.17003","article-title":"Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared with Azacitidine Monotherapy: Real-World Experience","volume":"44","author":"Baba","year":"2024","journal-title":"Anticancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1007\/s00277-025-06543-3","article-title":"Comparative efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia treatment: A meta-analysis of clinical trials and Real-World outcomes","volume":"104","author":"Simal","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1182\/bloodadvances.2025016879","article-title":"Antileukemic therapies for older adults with AML ineligible for conventional therapy: Systematic review and meta-analysis","volume":"10","author":"Oliveros","year":"2026","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"108145","DOI":"10.1016\/j.leukres.2025.108145","article-title":"Outcomes of adults older than 70 years of age undergoing allogeneic stem cell transplantation","volume":"160","author":"Bhatia","year":"2026","journal-title":"Leuk. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1080\/10428194.2021.2012666","article-title":"Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015\u20132020","volume":"63","author":"Huntington","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1002\/cncr.32439","article-title":"Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis","volume":"125","author":"Zeidan","year":"2019","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ajh.24767","article-title":"Early mortality and oerall survival of acute myeloid leukemia based on facility type","volume":"92","author":"Bhatt","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Diekmann, B., Veeger, N., Rozema, J., Kibbelaar, R., Franken, B., Guler, Y., Adema, B., van Roon, E., and Hoogendoorn, M. (2024). The Evolution of Treatment Policies and Outcomes for Patients Aged 60 and Older with Acute Myeloid Leukemia: A Population-Based Analysis over Two Decades. Cancers, 16.","DOI":"10.3390\/cancers16233907"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41375-024-02230-w","article-title":"Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients","volume":"38","author":"Shimony","year":"2024","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"102196","DOI":"10.1016\/j.jgo.2025.102196","article-title":"Describing the outcomes of frail patients undergoing treatment with systemic therapies for acute myeloid leukaemia: A systematic review","volume":"16","author":"Sia","year":"2025","journal-title":"J. Geriatr. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.26079","article-title":"Determination of fitness and therapeutic options in older patients with acute myeloid leukemia","volume":"96","author":"Cortes","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Hao, Q., Foroutan, F., Han, M.A., Devji, T., Nampo, F.K., Mukherjee, S., Alibhai, S.M.H., Rosko, A., Sekeres, M.A., and Guyatt, G.H. (2022). Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0278578"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1038\/s41375-025-02730-3","article-title":"Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model","volume":"39","author":"Venditti","year":"2025","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1200\/JCO.2017.72.7149","article-title":"Health Care Use by Older Adults with Acute Myeloid Leukemia at the End of Life","volume":"35","author":"Wang","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1089\/jpm.2021.0249","article-title":"Factors Associated with Health Care Utilization at the End of Life for Patients with Acute Myeloid Leukemia","volume":"25","author":"Vaughn","year":"2022","journal-title":"J. Palliat. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood-2018-03-842575","article-title":"Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia","volume":"132","author":"LeBlanc","year":"2018","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/cncr.29913","article-title":"Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database","volume":"122","author":"Fletcher","year":"2016","journal-title":"Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e2541719","DOI":"10.1001\/jamanetworkopen.2025.41719","article-title":"Perceived Value of Transfusion Access and Hospice Services Among Patients with Blood Cancers","volume":"8","author":"Raman","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpainsymman.2023.09.024","article-title":"Perspectives on Transfusions for Hospice Patients with Blood Cancers: A Survey of Hospice Providers","volume":"67","author":"Knight","year":"2024","journal-title":"J. Pain Symptom Manag."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/cncr.30735","article-title":"Why are patients with blood cancers more likely to die without hospice?","volume":"123","author":"Odejide","year":"2017","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1002\/cncr.29430","article-title":"Health care utilization and end-of-life care for older patients with acute myeloid leukemia","volume":"121","author":"Abel","year":"2015","journal-title":"Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3230\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:33:14Z","timestamp":1791459194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":44,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cancers18193230"],"URL":"https:\/\/doi.org\/10.3390\/cancers18193230","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]}}}